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Podocyte depletion is a major mechanism driving
glomerulosclerosis. Progression is the process by which
progressive glomerulosclerosis leads to end stage kidney
disease (ESKD). In order to determine mechanisms
contributing to persistent podocyte loss, we used a human
diphtheria toxin transgenic rat model. After initial diphtheria
toxin-induced podocyte injury (over 30% loss in 4 weeks),
glomeruli became destabilized, resulting in continued
autonomous podocyte loss causing global podocyte
depletion (ESKD) by 13 weeks. This was monitored by urine
mRNA analysis and by quantitating podocytes in glomeruli.
Similar patterns of podocyte depletion were found in the
puromycin aminonucleoside and 5/6 nephrectomy rat
models of progressive end-stage disease. Angiotensin II
blockade (combined enalapril and losartan) restabilized the
glomeruli, and prevented continuous podocyte loss and
progression to ESKD. Discontinuing angiotensin II blockade
resulted in recurrent glomerular destabilization, podocyte
loss, and progression to ESKD. Reduction in blood pressure
alone did not reduce proteinuria or prevent podocyte loss
from destabilized glomeruli. The protective effect of
angiotensin II blockade was entirely accounted for by
reduced podocyte loss. Thus, an initiating event resulting in a
critical degree of podocyte depletion can destabilize
glomeruli and initiate a superimposed angiotensin
II-dependent podocyte loss process that accelerates
progression resulting in eventual global podocyte depletion
and ESKD. These events can be monitored noninvasively in
real-time through urine mRNA assays.
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Compelling evidence now supports the concept that a major
cause of glomerulosclerosis is podocyte injury and depletion
from glomeruli.1–33 However, the mechanism of progression
to end-stage kidney disease (ESKD) is poorly understood.
Progression of glomerular diseases is the mechanism by
which cumulative glomerular injury results in progressive
loss of kidney function eventually resulting in ESKD. It is
manifest by an increasing proportion of glomeruli becoming
sclerotic over time and with downstream-associated loss of
renal tubules and their replacement by interstitial fibrosis. As
the major cause of glomerulosclerosis is podocyte injury and
depletion, and progression is due to progressive glomerulo-
sclerosis, we hypothesized that progression may be caused by
continual podocyte loss over time, which in turn results in
progressively more glomerulosclerosis, leading eventually to
global podocyte depletion and ESKD. We previously reported
data to support this general concept through urine messenger
RNA (mRNA) assays developed to monitor podocyte loss.33
However, if the continuous podocyte depletion hypothesis
for progression is correct, then it must also explain how
angiotensin II blockade ameliorates progression. Rigorous
testing of this hypothesis is central to understanding the
progression process and developing improved strategies for
monitoring and preventing progression in the clinic.
RESULTS
Persistent podocyte depletion following initiation of injury in
the hDTR Fischer 344 rat model
Initiation of glomerular injury was induced by intravenous
injection of diphtheria toxin (DT, 25 ng/kg) into human
diphtheria toxin receptor (hDTR) transgenic rats to
deplete 30–40% of podocytes by 4 weeks (Figure 1a–c). The
glomerular podocyte complement was measured by estimat-
ing WT1-positive nuclei per glomerulus (Figure 1b), and by
measuring podocyte area as a percentage of the glomerular
tuft area using the podocyte-specific marker GLEPP1
(glomerular epithelial protein 1) using immunoperoxidase
staining (Figure 1c). A priori one would expect that follow-
ing an episode of podocyte depletion there would be
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time-limited development of proteinuria and podocyte loss,
followed by a healing phase associated with glomerulo-
sclerosis proportional to the amount of initial podocyte
depletion. However, this is not what we observed. Sequential
kidney biopsies at 4, 8, and 13 weeks revealed that the
glomerular podocyte complement continued to autono-
mously decrease long after the initial insult was over, so that
progressively fewer podocytes remained at successive time
points as assessed by the two independent quantitative
methods (Figure 1b and c). Thus, an initial podocyte
depletion event resulted in apparent glomerular destabiliza-
tion such that glomeruli continued to lose podocytes over
time in spite of no further initiating injury. By 13 weeks,
glomeruli had become globally depleted of podocytes in
association with marked glomerulosclerosis, interstitial
fibrosis, and ectatic tubules typical of the end-stage kidney.
Measurement of specific podocyte markers (nephrin and
podocin) in urine allowed daily noninvasive assessment of
podocyte loss in the model (Figure 1d). Initial acute
podocyte injury was accompanied by increased nephrin, as
well as podocin mRNAs in urine. Persistent podocyte loss
during the chronic progression phase from 4–13 weeks was
associated with high levels of podocin mRNA, but not
nephrin mRNA, in urine as previously reported.33 This
difference in expression of two podocyte-specific markers is
conveniently captured as the podocin/nephrin mRNA ratio.
The continuously elevated urine podocin and podocin/
nephrin mRNA ratios in the chronic phase of progression
in this model therefore reflect continuous podocyte loss from
the destabilized glomerulus. Thus, we can state from this
experiment that an initial episode of podocyte injury causing
30–40% podocyte depletion over the acute injury period (up
to 4 weeks) resulted in further progressive chronic podocyte
loss over time as measured by three different methods
(podocyte tuft number, podocyte area in the tuft, and urine
podocyte mRNA measurements).
To understand the level of podocyte injury required to
trigger persistent podocyte loss, a second experiment was
conducted using variable amounts of initial podocyte
depletion. When the initial podocyte depletion by 4 weeks
at biopsy was o20%, then progressive loss of podocytes did
not occur. In contrast, when initial podocyte depletion was
high (460%), rats reached ESKD before 8 weeks (Figure 2).
Figure 3a shows the time course of additional bio-
markers including aquaporin 2 mRNA as a control tubular
biomarker, which did not change throughout the time
course, except to decrease toward ESKD in association with
reduced residual nephron mass. Urine transforming growth
factor (TGF)b1 mRNA was used as a biomarker for the
profibrotic milieu associated with progression and increased
as expected. Control values for each parameter measured
over the time course of the progression process are also
provided in Figure 3a.
In control studies (Supplementary Figure S1 online), we
evaluated the effect of proteinuria per se on the urine mRNA
biomarkers in the short term using the bovine serum
albumin protein overload rat model. Increasing the urine
protein/creatinine ratio to 480 caused by bovine serum
albumin injection into the peritoneal cavity of rats did
not significantly change urine podocin, podocin/nephrin
ratio, or TGFb1 mRNA urine biomarkers. In contrast, a
proximal tubular cationic amino acid transporter (Slc7a13)
mRNA increased 4100-fold in association with proteinuria.
These data show that the changes in urine mRNA bio-
markers observed were not a nonspecific consequence of
proteinuria per se.
We conclude that in the hDTR rat model an initiating
episode of podocyte depletion above a threshold level
(B30%) can promote autonomous long-term podocyte loss
from glomeruli, resulting eventually in global podocyte
depletion and ESKD, and that this process can be monitored
noninvasively through urine podocyte mRNAs.
Persistent podocyte loss and progression in the puromycin
aminonucleoside model
To confirm that the conclusions drawn in the hDTR
transgenic Fischer 344 rat were reproducible in another
model system, we induced progression in Sprague–Dawley
(SD) rats using puromycin aminonucleoside (PAN). Results
are shown in Figure 3b and Supplementary Figure S2 online.
Progression to ESKD was associated with persistent podocin
mRNA loss in the urine. High levels of nephrin were
only present in the acute phase after PAN injection (as
previously found for the hDTR rat model). The urine
podocin/nephrin ratio remained elevated throughout the
progression time course. By the time rats reached ESKD,
glomeruli were globally depleted of podocytes as previously
observed for the hDTR model. Similar changes in urine
podocyte and TGFb1 mRNAs were also present as previously
seen with the hDTR model system. Urine AQP2 was increased
in the acute phase (after PAN injection), which could reflect a
direct toxic effect of PAN on tubules themselves (Figure 3b). In
the progression phase, similar patterns of urine mRNAs were
present in the PAN model in the SD rats as had been
documented with the hDTR model in the Fischer 344 rats.
Persistent podocyte loss and progression in the 5/6
nephrectomy model
The hDTR and PAN models are both initiated by direct
podocyte injury. Progression in the 5/6 nephrectomy model
is initiated by removal of 5/6ths of kidney mass, thereby
resulting in remaining kidney hypertrophy and progression
to ESKD over time. To determine whether podocyte
depletion occurs in this model, we measured the same
parameters as those used in the two previous models. As
shown in Figure 3c and Supplementary Figure S3 online,
the same stigmata of progression were seen in the 5/6
nephrectomy model as in the hDTR and PAN models.
Progression was associated with persistent loss of podocytes
from glomeruli as measured by an elevated level of urine
podocin and podocin/nephrin mRNA ratios and persistently
high urine TGFb1 mRNA levels, proteinuria, development of
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marked hypertension, and a histological appearance of
glomerular enlargement, patchy loss of podocytes from
glomeruli, focal segmental glomerulosclerosis, and interstitial
scarring on Masson’s trichrome staining.
Data from three models in two rat strains are compatible
with the conclusion that progression is driven by persistent
podocyte loss over time, resulting in progressive glomerulo-
sclerosis and secondary interstitial fibrosis.
Prevention of autonomous podocyte loss by angiotensin II
blockade
To test the hypothesis that angiotensin II blockade might
mitigate autonomous podocyte loss observed in the hDTR
model, we used a combination of an angiotensin converting
enzyme inhibitor (enalapril at 10 mg/kg/day) and an
angiotensin II receptor blocker (losartan at 50 mg/kg/day)
delivered in drinking water. Drug treatment was not started
until 5 days after intravenous DT injection in order to ensure
that DT access to podocytes would not be affected by drug
effects on glomerular filtration rate. Figure 4 shows that the
drug combination reduced proteinuria starting 5 days after
initiation of drug treatment, reflecting hemodynamic effects
of the drug on glomerular filtration of proteins. Blood
pressure was also reduced in a similar time frame. Thus, there
was a robust impact of drug treatment as assessed by
physiological parameters. However, it was not until after day
21 (16 days after the start of drug treatment) that there was a
measurable impact of drug on reducing urine podocyte
mRNA levels for both nephrin and podocin relative to non-
drug-treated rats. This time lag suggests that time-dependent
biological processes other than solely hemodynamic factors
may be responsible. After day 21, angiotensin II blockade had
a marked and persistent effect on reducing the urine
podocyte biomarker levels including the urine podocin/
nephrin mRNA ratio through 9 weeks after initiation of
injury.
Figure 4a shows representative histological analysis of
drug-treated and non-drug-treated kidneys. The upper
panels demonstrate that the non-drug-treated rats had few
podocytes remaining in glomeruli by 9 weeks, whereas drug-
treated rat glomeruli had only minor focal and segmental
patchy loss of podocytes from glomerular tufts detected by
GLEPP1 peroxidase staining. Masson’s trichrome-stained
sections demonstrated typical features of the end-stage
kidney with glomerular sclerosis and interstitial fibrosis in
non-drug-treated rats. In contrast, drug-treated rats had only
small areas of focal and segmental glomerulosclerosis with
glomeruli remaining largely intact and the interstitial
compartment being essentially normal.
Figure 4b and c documenting quantification of the
podocyte complement by two methods showed that drug-
treated rats had only lost about 30% of their podocytes
following DT injection, as compared with loss of 70–80% in
non-drug-treated rats (Figure 4b and c). Quantification of
the urine podocin mRNA loss showed a similar reduction in
podocyte loss in the drug-treated rats as was seen by
histological methods, thereby confirming that the three
methods of monitoring podocyte loss were congruent.
From this result, we concluded that glomeruli that were
destabilized by a critical degree of podocyte depletion, so they
would continue to lose podocytes over time until ESKD (as
occurred in the control arm of this experiment), could be
restabilized by angiotensin II blockade such that they no
longer lost podocytes autonomously. If this concept is
correct, then we might expect that discontinuing angiotensin
II blockade after a period of stabilization would reverse the
stabilization effect. We therefore used the same protocol to
stabilize glomeruli for 8 weeks after DT-induced podocyte
depletion, at which time a kidney biopsy was performed to
confirm equal injury in both groups. At this point, drug was
discontinued in one group. Figure 5 shows that on
discontinuing angiotensin II blockade, proteinuria immedi-
ately increased in association with an increase in urine
podocyte biomarkers including the urine podocin/nephrin
mRNA ratio. Increased podocyte loss and worse histological
appearance in the drug-discontinued group was confirmed
by quantification of the podocyte complement (Figure 5).
Thus, angiotensin II blockade started 5 days after
initiation of podocyte injury did not affect the initial acute
phase podocyte loss following DT injection. However,
angiotensin II blockade markedly reduced the autonomous
chronic phase of podocyte loss in association with protection
of kidneys from progression to ESKD. Furthermore, if
angiotensin II blockade treatment was stopped, glomeruli
became destabilized again with recurrence of progressive
podocyte loss leading to glomerulosclerosis.
Figure 1 |Autonomous progression following initial podoctyte depletion in the hDTR Fischer 344 rat model. (a) Representative
histology for sequential kidney biopsies. From left to right, micrographs are from control and at 4, 8, and 13 weeks after diphtheria toxin
(DT) injection. Upper panels show podocytes identified using glomerular epithelial protein 1 (GLEPP1)/peroxidase. Lower panels show
Masson’s trichrome staining. Arrows show sclerosed and partially sclerosed glomeruli. The boxes show higher magnification of an individual
glomerulus. (b) Quantification of histology using WT1-positive podocyte nuclear number. (c) Percentage of glomerular tuft area that was
GLEPP1 positive. (d) Time course of urine protein/creatinine ratio, urine podocyte (podocin and nephrin) mRNA excretion, and urine
podocin/nephrin mRNA ratio. Note that the urine protein/creatinine ratio was increased after injury and continued at a high level until end-
stage kidney disease at 13 weeks (top). In the acute phase (first 21 days after injury), both podocin and nephrin mRNA levels were increased.
During the chronic phase of progression (from 4 to 13 weeks), urine podocin mRNA remained elevated throughout the time course of
progression showing autonomous podocyte loss over the entire time course. In contrast, nephrin mRNA levels were not correspondingly
increased during the chronic phase, and thus the urine podocin/nephrin mRNA ratio is a marker of the chronic progression phase. n¼ 8,
*Po0.05 and **Po0.01, as assessed by Kruskal–Wallis test and then Scheffe’s test. The serum creatinine values in these animals were
2.52±0.36mg/dl vs. 0.43±0.06mg/dl in the normal controls (Po0.01, as assessed by Student’s t-test). NS, nonsignificant.
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Blood pressure reduction and podocyte depletion
To assess the effect of blood pressure reduction on podocyte
loss, we first used the classical triple therapy regimen
(hydralazine at 40 mg/kg/day, reserpine at 1.3 mg/kg/day,
and hydrochlorothiazide at 17 mg/kg/day) delivered in the
drinking water. Drug treatment was again started 5 days after
initiation of injury. Figure 6 shows that triple therapy
significantly reduced blood pressure in the acute phase but
became ineffective in the chronic phase when blood pressure
in treated and non-treated groups both increased in parallel.
Proteinuria, histological parameters, renal function, and
urine podocyte mRNA levels were not protected in the
drug-treated group.
In a second experiment (Figure 7), we used the renin
inhibitor aliskiren, started 5 days after initiation of injury,
which was delivered by osmotic minipump for 8 weeks. The
effect of aliskiren (25 mg/kg/day) was compared with losartan
(50 mg/kg/day) and to a combination of losartan and
aliskiren. Aliskiren alone reduced systolic blood pressure to
the normal range throughout the study period. However,
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Figure 2 | The effect of variable amounts of initial podocyte depletion in hDTR rat model. (a) Glomerular podocyte number measured
by WT1-positive nuclei immunofluorescence staining in severe (n¼ 5), moderate (n¼ 13), mild (n¼ 5), and control (n¼ 4) groups at 4 and 8
weeks. #Po0.05. (b) Percentage of glomerular tuft area that was glomerular epithelial protein 1 (GLEPP1) positive in severe, moderate, mild,
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moderate, mild, and control groups. (f) Mean daily urine podocin/nephrin mRNA ratio in severe, moderate, mild, and control groups.
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NS, nonsignificant.
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aliskiren did not reduce proteinuria or urine podocyte
markers, and did not significantly reduce glomerular
podocyte loss or glomerulosclerosis. In contrast, losartan
alone reduced blood pressure by a similar amount to aliskiren
alone, but also reduced proteinuria, the rate of podocyte loss
as assessed by urine mRNA markers, the degree of podocyte
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Figure 4 |Prevention of autonomous podocyte depletion by angiotensin II blockade. (a) Representative histology with or without
angiotensin II blockade in the hDTR rat model. Upper panels show podocytes identified using glomerular epithelial protein 1 (GLEPP1)/
peroxidase. Lower panels show Masson’s trichrome staining. Arrows show sclerosed and partially sclerosed glomeruli. The boxes show
higher magnification of an individual glomerulus. (b) Quantification of histology with or without angiotensin II blockade by WT1-positive
nuclei immunofluorescence staining. (c) Percentage of glomerular tuft area that was GLEPP1 positive. (d) Time course of urine protein/
creatinine ratio, urine podocyte (podocin and nephrin) mRNA excretion, and urine podocin/nephrin mRNA ratio with or without angiotensin
II blockade. Note that the drug-treated group showed reduced proteinuria by about 5 days after the start of drug treatment. In the acute
phase (the first 21 days after injury), urine podocyte mRNA (podocin and nephrin) excretion was not significantly different; however, in the
chronic phase (after 21 days), urine podocyte mRNAs and urine podocin/nephrin mRNA ratio were significantly reduced in the drug-treated
group. (e) Acute and chronic phase analysis of the urine protein/creatinine ratio, urine podocyte mRNAs, and urine podocin/nephrin mRNA
ratios. (f) Time course of systolic blood pressure with or without angiotensin II blockade. n¼ 7 per group, *Po0.05 and **Po0.01, as
assessed by Student’s t-test. ##Z43 as assessed by Z-statistical analysis. The serum creatinine values in non-drug-treated animals were
2.60±0.14mg/dl vs. 0.73±0.04mg/dl in the drug-treated animals (Po0.01, as assessed by Student’s t-test). ACE, angiotensin converting
enzyme; ARB, angiotensin receptor blocker; NS, nonsignificant.
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NS, nonsignificant.
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show podocytes identified using glomerular epithelial protein 1 (GLEPP1)/peroxidase staining. Lower panels show Masson’s trichrome
staining. Arrows show sclerosed and partially sclerosed glomeruli. The boxes show higher magnification of an individual glomerulus.
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nuclear immunofluorescence. (c) Percentage of glomerular tuft area that was GLEPP1 positive. (d) Time course of urine protein/creatinine
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depletion as assessed by podocyte counting in histological
sections, and the degree of glomerulosclerosis.
The failure of aliskiren to reduce proteinuria and prevent
podocyte loss and glomerulosclerosis in these experiments
could reflect the fact that aliskiren has a 4100-fold lower
affinity for rat renin than human renin.34 Therefore, renin
inhibition within rat glomeruli in these experiments may
simply not have been adequate to prevent critical concentra-
tions of intraglomerular angiotensin II from being generated,
while at the same time being adequate to lower systemic
blood pressure. Aliskiren may also have affected brain
renin activity, which has recently been shown to have a role
in regulating systemic blood pressure.35 However, these
experiments do demonstrate conclusively that reduction of
systemic blood pressure alone into the normal range was not
sufficient to prevent autonomous podocyte loss once
glomeruli had been destabilized by a critical degree of
podocyte injury.
Is preventing podocyte loss a major mechanism by which
angiotensin II prevents progression in the hDTR model?
Figure 8a and b demonstrate that following threshold
depletion of B30% of podocytes, there was a strong linear
relationship between further podocyte depletion and the
development of both glomerular and interstitial fibrosis
(R2¼ 0.77 and 0.61, respectively). Figure 8c and d demon-
strate that the relationship between podocyte loss and both
glomerulosclerosis and interstitial fibrosis was not signifi-
cantly altered irrespective of whether animals had been
treated with angiotensin II blockade. These data are therefore
compatible with the conclusion that the protective effect
of angiotensin II blockade in this model system occurred
predominantly through preventing podocyte loss rather than
through a podocyte depletion-independent mechanism.
Does the high podocin/nephrin mRNA ratio in urine reflect an
altered ratio within the renal cortex during progression, and
is this affected by angiotensin II blockade?
Glomerular nephrin is well known to be downregulated in
association with chronic glomerular diseases such as diabetic
glomerulosclerosis.36–42 Therefore, we evaluated whether in
the hDTR model system nephrin is relatively downregulated
during progression in the renal cortex. The podocin/nephrin
mRNA ratio in renal cortex of progressing animals (n¼ 7)
was significantly higher than the podocin/nephrin mRNA
ratio in control rats (n¼ 5; 5.15±0.44 vs. 1.14±0.11,
Po0.001). Angiotensin II blockade (n¼ 8) decreased the
cortical podocin/nephrin mRNA ratio (2.60±0.45 vs.
5.15±0.44, Po0.001), but did not return it to baseline
(2.60±0.45 vs. 1.14±0.11, P¼ 0.03). Furthermore, the
nephrin/GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase) mRNA ratio in renal cortex was decreased 18-fold in
progressing rats compared with control (0.001±0.0003 vs.
0.018±0.002, Po0.01), whereas the podocin/GAPDH
mRNA ratio was decreased only 3-fold (0.007±0.001 vs.
0.021±0.002, Po0.01) in association with progression.
These data are compatible with the conclusion that nephrin
mRNA expression is preferentially reduced compared with
podocin mRNA expression in renal cortex during progres-
sion, resulting in a high podocin/nephrin mRNA ratio in
both renal cortex and in urine of progressor rats, and that
angiotensin II has a role in driving these events.
DISCUSSION
We demonstrate that following a critical degree of podocyte
depletion, the glomerulus can become destabilized, resulting
in continued persistent podocyte loss without further insult
until glomeruli become globally depleted of podocytes
(autonomous progression to ESKD). This autonomous
podocyte loss process was prevented by angiotensin II
blockade. Once destabilized by a critical degree of podocyte
depletion, continuous angiotensin II blockade was required
for glomeruli to remain stable. Stopping angiotensin II
blockade resulted in renewed podocyte loss and further
progressive loss of kidney function. The protective effect of
angiotensin II blockade was not due to blood pressure
reduction alone, as reducing blood pressure to the normal
range, even by the renin inhibitor aliskiren, did not prevent
persistent podocyte loss and progression. Thus, angiotensin
II blockade, probably functioning directly on the podocyte,
appears to be necessary for optimal prevention of podocyte
loss following initial podocyte injury. These concepts,
illustrated diagramatically in Figure 9, outline how a critical
degree of glomerular injury from any cause can be amplified
by angiotensin II-dependent further podocyte depletion, and
how this process can be monitored noninvasively through
urine mRNA biomarkers. These concepts also provide a
mechanistic explanation for the ‘hyperfiltration hypothesis’
of Brenner et al.43
The two major functions of the glomerulus are filtration
of blood and volume control via the juxtaglomerular
apparatus. Changes in intraglomerular dynamics caused by
podocyte depletion and protein leak into the filtrate result in
activation of the renin–angiotensin system, as is well
described in the nephrotic syndrome. Mechanistically,
angiotensin II would cause increased intraglomerular pres-
sure, as well as direct effects on glomerular cells through
angiotensin receptors. For example, the podocyte has both
AT1 and AT2 receptors;44–46 overexpression of AT1 receptors
by podocytes causes glomerulosclerosis;45 in podocyte cell
culture systems, angiotensin II modifies cytoskeletal structure
and the podocyte phenotype in an epithelial-mesenchyme
transformation-like manner, and causes downregulation of
nephrin expression;46–49 and nephrin expression is well
documented to be downregulated in chronic glomerular
diseases.36–42 We also demonstrate that progression was
associated with relative cortical nephrin mRNA downregula-
tion in comparison with podocin mRNA, and this was
ameliorated by angiotensin II blockade. These data all
support the concept that one mechanism driving autono-
mous podocyte loss is an effect of angiotensin II in causing a
podocyte phenotypic switch that results partly in nephrin
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downregulation. The time delay between angiotensin
II-induced hemodynamic effects (reduced proteinuria/blood
pressure) and reduced podocyte loss in urine, and the fact
that lowering systemic blood pressure to the normal range
did not reduce the rate of podocyte loss, also support the
hypothesis that reducing blood pressure and even reduced
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intraglomerular pressure (as judged by reduced protein-
uria) may not itself be sufficient to prevent podocyte
loss from the destabilized glomerulus. Additional effects of
angiotensin II blockade in modulating the podocyte
phenotype may also be required. Stopping angiotensin II
blockade resulted in rapid rebound destabilization of
glomeruli and triggered further podocyte loss, compatible
with the clinical concept that maintaining angiotensin II
blockade long term in patients with previously destabilized
glomeruli can prevent or retard subsequent glomerular and
interstitial fibrosis.
The angiotensin II-dependent mechanism described in
this report would likely be different from the ‘podocyte
damage damages podocyte’ concept reported by Ichikawa
et al,13 who used a chimeric mouse model to demonstrate
that damage to a podocyte results in damage to its
neighboring poodcyte (‘vicious cycle of podocyte-to-podo-
cyte damage’). Matsusaka et al.14 used podocyte-specific
Figure 7 |Blood pressure reduction throughout the time course using aliskiren (delivered at 25mg/kg/day by osmotic minipump)
did not reduce proteinuria or prevent autonomous podoyte depletion. In contrast, similar blood pressure reduction using the
angiotensin II receptor blocker losartan reduced proteinuria and podocyte depletion. (a) Representative histology in saline, aliskiren,
losartan, and aliskirenþ losartan groups. Upper panels show podocytes identified using glomerular epithelial protein 1 (GLEPP1)/peroxidase
staining. Lower panels show Masson’s trichrome staining. Arrows show sclerosed and partially sclerosed glomeruli. The boxes show higher
magnification of an individual glomerulus. Color coding is shown by the box at upper right for the saline, aliskiren, losartan, and
aliskirenþ losartan groups. (b) Quantification of glomerular podocyte number by WT1-positive nuclear immunofluorescence. (c) Percentage
of glomerular tuft area that was GLEPP1 positive. (d) Quantification of glomerular sclerosis score. (e) Quantification of interstitial fibrosis
score. (f) Time course of urine protein/creatinine ratio, urine podocyte (podocin and nephrin) mRNA excretion, and urine podocin/nephrin
mRNA ratio. Aliskiren alone did not reduce proteinuria or urine podocyte markers. In contrast, losartan alone and aliskirenþ losartan
reduced proteinuria and urine mRNA markers. (g) Acute and chronic phase analysis of the urine protein/creatinine ratio, urine podocyte
mRNAs, and urine podocin/nephrin mRNA ratio. (h) Time course of systolic blood pressure showing significant reduction of blood pressure
to the normal range throughout the time course in aliskiren, losartan, and aliskirenþ losartan group rats. n¼ 8 (saline and aliskiren groups),
n¼ 6 (losartan and aliskirenþ losartan groups). *Po0.05 and **Po0.01, as assessed by Kruskal–Wallis test and then Scheffe’s test. #Z42
as assessed by Z-statistical analysis. The serum creatinine values in these four groups were 2.64±0.29, 2.14±0.13, 1.29±0.07, and
1.33±0.10mg/dl (Po0.01, saline vs. losartan and saline vs. aliskirenþ losartan, Po0.05, aliskiren vs. losartan, as assessed by Kruskal–Wallis
test and then Scheffe’s test). DT, diphtheria toxin; NS, nonsignificant.
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Figure 8 |Relationship between glomerular sclerosis or interstitial fibrosis score and percentage depletion of the WT1 podocyte
nuclear count. (a) Relationship between glomerular sclerosis score and percentage depletion of WT1 podocyte nuclear count for all
animals (n¼ 87, R2¼ 0.79, Po0.001). (b) Relationship between interstitial fibrosis score and percentage depletion of WT1 podocyte nuclear
count for all animals (n¼ 87, R2¼ 0.61, Po0.001). (c) Relationship between glomerular sclerosis score and percentage depletion of podocyte
count with (closed squares and thick line) or without (open triangles and thin line) angiotensin II blockade. Angiotensin II blockade
caused reduced podocyte loss but did not change either the slope or the coordinates of the correlation (non-drug group: n¼ 57, R2¼ 0.81,
Po0.001; drug group: n¼ 30, R2¼ 0.63, Po0.001). (d) Relationship between interstitial fibrosis score and percentage depletion of
WT1 podocyte nuclear count with (closed squares and thick line) or without (open triangles and thin line) angiotensin II blockade.
Angiotensin II blockade reduced podocyte loss but did not change the slope of the relationship (non-drug group: n¼ 57, R2¼ 0.57,
Po0.001; drug group: n¼ 30, R2¼ 0.44, Po0.001).
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deletion of the AT1 receptor in a mouse toxin model to
suggest that direct effect of angiotensin II on podocytes may
not be responsible for podocyte injury. However, these
studies do not exclude an effect through podocyte AT2
receptors, and the experimental design for these studies used
pretreatment of mice by losartan 5 days before toxin
injection, raising the possibility that angiotensin II blockade
could have modified glomerular filtration of the 60 kDa toxin
and thereby reduced access of the toxin to podocytes.14
Thus, the precise mechanism by which angiotensin II drives
podocyte injury and loss remains to be unequivocally
established.
Angiotensin II is capable of driving the profibrotic process
through different mechanisms.50 Our data are compatible
with the conclusion that the predominant protective effect of
angiotensin II blockade occurred through preventing podo-
cyte depletion and its downstream consequences. Mecha-
nistically, this could occur through downstream effects of
podocyte loss-induced proteinuria in driving interstitial
fibrosis as described by Eddy,51 protein leak into the peri-
glomerular and interstitial space as a driver of interstitial
fibrosis as described by Kriz and LeHir,10 and through TGFb
expression in relation to these processes.52
In the hDTR and PAN model systems, all glomeruli
become simultaneously depleted of podocytes. The clinical
syndrome revealed by these models resembles rapidly
progressive glomerular diseases such as those that are seen
clinically in association with crescentic nephritis and other
conditions wherein podocytes become depleted from
glomeruli over relatively short periods of time. For example,
in crescentic nephritis, podocytes are lost into the crescent
and change their phenotype;53–56 in HIV-associated nephro-
pathy, podocytes switch their phenotype to lose podocyte
markers and presumably podocyte function;57,58 and in
severe inflammatory conditions, podocytes are lost in
increased quantities into the urine.13,14 However, in many
human glomerular diseases, the underlying progression
process occurs over months or years, and the glomerular
lesions are typically focal and segmental (affecting different
glomeruli to different degrees at different times), such as
those that were observed in the 5/6 nephrectomy model in
this report and in the aging model in ad libitum-fed rats.59
We expect that the same mechanism and time course of
autonomous podocyte loss from destabilized glomeruli will
occur for an individual glomerulus, or a capillary loop within
a glomerulus, in chronic glomerular diseases, as was observed
for the whole population of glomeruli in the hDTR model.
Thus, the difference in clinical phenotype of slow vs. rapid
progression is probably due to the same underlying biology
taking place in single glomeruli or parts of glomeruli,
as opposed to a large proportion of glomeruli, at any point in
time.
The potential clinical utility of urine podocyte mRNAs
(and particularly the urine podocin/nephrin mRNA ratio) to
noninvasively monitor events taking place in the glomerulus
in real time is supported by the data shown. It is clear that
these studies, which use a limited pastiche of urine mRNAs to
describe the podocyte, can potentially provide a rich source
of information about glomerular biology, which may include
both the rate of podocyte loss and podocyte stress, as well as
podocyte replacement from parietal epithelial stem cells and
other sources. If these markers can be reliably harnessed, they
could provide a new paradigm for noninvasive monitoring
and management of glomerular diseases.
MATERIALS AND METHODS
Animals
All animal studies were approved by the University of Michigan
Committee on Use and Care of Animals. All drug treatment was
started 5 days after intravenous DT injection. We performed
daily urine collection for 3 weeks, followed by 4 days/week urine
collection until the end of each study. Systolic blood pressure,60
serum and urine creatinine, and urine protein were measured as
described previously.11,33
hDTR Fischer 344 rat model
For standard protocol, heterozygous 100 g hDTR transgenic rats
received 25 ng/kg DT injected intravenously in normal saline (0.9%)
containing 0.1 mg/ml rat albumin as a carrier. Kidney biopsies were
performed to remove approximately one-tenth of one kidney at 4
and 8 weeks, and kidneys were harvested at 13 weeks. Timed urine
samples were also collected from control Fisher 344 rats (n¼ 5)
2 days per week for 13 weeks. Data are shown in Figure 3a as the
mean weekly value. In a second experiment to obtain a range of
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Figure 9 |Diagrammatic summary of the glomerular
destabilization and progression hypothesis. Many factors can
cause podocyte injury. If as a result of this initiating injury there is
a critical level of podocyte depletion, then the glomerulus can
become destabilized such that further podocyte loss occurs
independent of the initiating event and driven by the
renin–angiotensin system until glomeruli become globally
depleted of podocytes (end-stage kidney disease, ESKD).
This progression-accelerating mechanism can be retarded or
prevented by angiotensin II (AngII) blockade (glomerular
restabilization), but discontinuation of angiotensin II blockade
results in relapse to the destabilized glomerular phenotype with
recurrence of podocyte loss. These events can be monitored
noninvasively by measuring the podocyte mRNA products in
urine.
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podocyte depletion, the DT doses used were 25–40 ng/kg intrave-
nously (n¼ 12) or intraperitoneally (n¼ 11) as previously de-
scribed.31 These rats (n¼ 27) were divided into three groups based
on the degree of podocyte depletion at 4 weeks (control, mild
o20%, moderate 20–60%, and severe 460%).
Angiotensin II blockade model
Rats receiving standard DT protocol were assigned to two groups:
drug group, receiving enalapril, 10 mg/kg/day (cat. no. E6888,
Sigma, St Louis, MO), and losartan, 50 mg/kg/day (provided by
Merck, Rahway, NJ) in drinking water, and non-drug group, not
receiving the drug. Animals in the non-drug-treated group reached
ESKD by 9 weeks after DT injection. In the second experiment,
standard protocol rats were assigned to the two groups: drug
continuation group and drug discontinuation group. Both groups
received enalapril and losartan in drinking water for 8 weeks.
Following a kidney biopsy, the drug continuation group continued
using the drug, whereas the drug discontinuation group stopped
using the drug. Rats were killed 19 weeks after DT injection.
Triple therapy treatment model
Rats receiving standard protocol were assigned to the two groups:
drug group, receiving hydralazine (40 mg/kg/day; cat. no. H1753,
Sigma), reserpine (1.3 mg/kg/day; cat. no. R0875, Sigma), and
hydrochlorothiazide (17 mg/kg/day; cat. no. H4759, Sigma) in
drinking water, and non-drug group, receiving water alone. Rats
were killed at 9 weeks after DT injection. In initial studies, adding
labetalol up to 80 mg/kg/day to the triple therapy regimen did not
lower blood pressure further (data not shown).
Aliskiren treatment model
Rats receiving standard protocol were assigned to the four groups: saline,
aliskiren alone, losartan alone, and aliskirenþ losartan. Drug-treated
groups received aliskiren 25 mg/kg/day (provided by Novartis Interna-
tional AG, Basel, Switzerland) or saline both delivered by osmotic
minipump (Alzet 2ml4 minpump (Alzet Osmotic Pumps, Cupertino,
CA) implanted subcutaneously under anesthetic and replaced after 4
weeks), or losartan 50 mg/kg/day in drinking water, or aliskiren by
minipump and losartan in the drinking water. Rats were euthanized at 9
weeks after DT injection.
Protein overload model
Heterozygous 100 g hDTR Tg Fischer 344 rats received a daily
injection of 1 g/day fatty acid-free bovine serum albumin (cat. no.
A8806, Sigma) intraperitoneally for 4 days with daily urine
collection preceding and during 4 days of albumin injections. Rats
were euthanized at 4 days after albumin injection.
Puromycin aminonucleoside SD rat model
Male SD rats (100 g) received 20 mg/100 g PAN (cat. no. P7130,
Sigma) intraperitoneally. After 8 weeks, a kidney biopsy was done, and
then a second PAN injection (12.5 mg/100 g) was given intravenously
Rats were killed 69–105 days after the first PAN injection when they
reached ESKD. Timed urine samples were collected from control SD
rats (n¼ 5). Urine was collected 2 days per month for 16 weeks, with
the monthly mean value used as shown in Figure 3b.
5/6 Nephrectomy rat model
Two-thirds (extended poles) of the right kidney of SD male rats were
removed when they reached B100 g of weight. One week after the
partial right nephrectomy, the whole of left kidney was removed.
Urine and blood pressure measurements were recorded as described
for the hDTR model above. Rats were euthanized at 18 weeks after
5/6 nephrectomy. Timed urine samples were collected from control
SD rats (n¼ 5). Urine was collected 2 days per month for 16 weeks,
with the monthly mean value used as shown in Figure 3c.
RNA from urine sediments and cortex
Urine was collected overnight (average 15 h) and cortex was dissected
into small pieces after being perfused using cold phosphate-buffered
saline using methods previously described, except that total urine
pellet and cortex RNA was isolated using the protocol of the RNeasy
Mini Kit (cat. no. 74106; Qiagen, Hilden, Germany).31
Quantitative real-time PCR
Quantification of the absolute nephrin, podocin, TGFb1, aquaporin
2, Slc7a13, and GAPDH mRNA abundance was performed using
the 7900 HT Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA) using TaqMan Fast Universal PCR Master Mix,
with sample complementary DNA in a final volume of 10ml per
reaction. TaqMan Probes (Applied Biosystems) used were as follows:
Rat homolog for NPHS1 (nephrin) spanned exons 20–21 (cat. no.
Rn00575235_m1); rat homolog for NPHS2 (podocin) spanned
exons 3–4 (cat. no. Rn00709834_m1); rat TGFb1 spanned exons 1–2
(cat. no. Rn00572010_m1); rat aquaporin 2 spanned exons 1–2
(cat. no. Rn00563755_m1); rat Slc7a13 spanned exons 3–4 (cat. no.
Rn01764598_m1); and rat GAPDH was within exon 3 (cat. no.
Rn99999916_s1). All data were from 2 mg sample complementary
DNA. Standard curves were constructed using these serially
diluted standards.33 CT values were used to analyze mRNA levels
from standard curve using the SDS 2.2.2 software (Applied
Biosystems).
Histological analysis
Paraformaldehyde/lysine/periodate-perfused and fixed kidney, fol-
lowed by paraffin embedding for sectioning, was used as described
previously.11,33 WT1-positive podocyte nuclei per glomerular tuft
were counted as previously described using the following modifica-
tion.61 WT1 primary antibody and Cy3-labeled secondary antibody
were used to identify podocyte nuclei in 4,6-diamidino-2-pheny-
lindole-stained sections so that podocyte nuclei appeared as a
shocking pink color that facilitated identification in biopsy samples,
where blood components remain in glomerular capillaries and cause
nonspecific immunofluorescent signals. GLEPP1-positive tuft area
was estimated as previously described method.11,33,61 Glomerular
and interstitial fibrosis scoring was measured using 3-mm Masson’s
trichrome-stained sections. Mean glomerular fibrosis score was
estimated from 50 consecutive glomerular cross-sections. Interstitial
fibrosis score was estimated using the Metamorph imaging program
to measure the percentage of the non-glomerular cortex area that
stained blue in  10 images.
Statistical methods
All results were presented as means±s.e.m., except where otherwise
noted. Differences between two groups were tested using Student’s
t-test, and among more than two groups by Kruskal–Wallis test.
When the Kruskal–Wallis test was significant, Scheffe’s test was
carried out for post hoc analysis. A two-sample Z-statistic was used
to compare the mean levels in blood pressure data. Correlations
between parameters were compared by single regression analysis.
Po0.05 and Z42 was considered to be statistically significant.
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